Mesa Laboratories Acquires Agena Bioscience
September 14, 2021
Mesa Laboratories, Inc. (NASDAQ:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. for $300 million in cash. Agena, a San Diego–based molecular diagnostics and genomics tools company, is expected to add roughly $63–67 million of revenue (about 65% recurring) in the first 12 months and will form Mesa’s new Clinical Genomics Division.
- Buyers
- Mesa Laboratories, Inc.
- Targets
- Agena Bioscience, Inc.
- Industry
- Medical Devices
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Agilent Technologies Acquires Avida Biomed
January 4, 2023
Biotechnology
Agilent Technologies has acquired Avida Biomed, an early-stage developer of high-performance NGS target enrichment workflows for cancer research. The acquisition augments Agilent's SureSelect portfolio and expands its capabilities into high-growth clinical research and diagnostics markets by adding Avida's chemistries and automatable assays compatible with Agilent platforms.
-
ProPhase Labs Acquires Nebula Genomics
August 11, 2021
Biotechnology
ProPhase Labs, through its newly formed subsidiary ProPhase Precision Medicine, completed the acquisition of Nebula Genomics, a privately owned whole‑genome sequencing and personal genomics company. The deal (approximately $14.6 million in a mix of cash and ProPhase common stock) will integrate Nebula’s whole genome sequencing capabilities and DTC platform into ProPhase’s CLIA-certified molecular testing laboratories to expand diagnostic and consumer genomics offerings.
-
Mesa Laboratories Acquires Gyros Protein Technologies
October 31, 2019
Biotechnology
Mesa Laboratories (NASDAQ: MLAB) acquired Gyros Protein Technologies Holding AB (GPT) from AP6 (Sixth Swedish National Pension Fund), Ampersand Capital Partners and individual shareholders for $180 million in cash. The acquisition, which establishes Mesa's new Biopharmaceutical Development platform, adds GPT's immunoassay and peptide synthesis instruments and consumables and is expected to contribute roughly $37–$40 million of revenue in the first 12 months (about 55% recurring).
-
Amgen Acquires Teneobio for $900M with Up to $1.6B in Milestones
July 27, 2021
Biotechnology
Amgen agreed to acquire clinical-stage biotechnology company Teneobio for $900 million in upfront cash plus potential contingent milestone payments up to $1.6 billion. The acquisition adds Teneobio's heavy-chain antibody discovery platform, bispecific/multispecific antibody technologies and a Phase 1 T-cell engager (TNB-585), strengthening Amgen's antibody research capabilities and oncology pipeline.
-
Bionano Genomics Acquires BioDiscovery
October 12, 2021
Software
Bionano Genomics agreed to acquire BioDiscovery, a provider of NxClinical genomics analysis software, in a deal worth up to $100 million in cash and equity. The acquisition will integrate BioDiscovery's platform-agnostic analysis and reporting tools with Bionano's optical genome mapping technology to accelerate variant analysis and broaden Bionano's market reach; BioDiscovery founder Soheil Shams will join Bionano as Chief Informatics Officer.
-
LabCorp Acquires MNG Laboratories from HealthEdge
March 4, 2019
Healthcare Services
LabCorp has acquired MNG Laboratories, an Atlanta-based clinical diagnostic provider specializing in neurogenetics and next-generation sequencing, from HealthEdge Investment Partners' Fund II. The acquisition expands LabCorp’s neurology and neurogenetics testing capabilities and makes MNG’s testing services available through LabCorp’s Covance drug development business.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.